Market news
Detailed price information for Canadian National Railway (CNI-N) from The Globe and Mail including charting and trades.
Curis: Q2 Earnings Snapshot
Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of commo
The fair value price target for Curis has been reset from US$280.00 to US$42.67, which represents a very large downward adjustment in the modeled target level. Analysts link this shift to updated assumptions around emavusertib and the TakeAim chronic lymphocytic leukemia study, where price targets now reflect explicit probabilities of success, peak sales estimates and timing. As you read on, you will see how this evolving narrative around Curis might influence the way you track the stock from...
On Wednesday, Curis Inc. announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance. The biotechnology firm detailed key advances across its ongoing clinical programs evaluating the oral IRAK4 and FLT3 inhibitor for targeted...
Curis gained attention after positive emavusertib data as analyst raised its price target to $43 and highlighted upcoming trial catalysts.
Curis shares positive updated clinical data for emavusertib and increases its year-end guidance for the TakeAim CLL study.
Curis is back in focus after analysts lifted their fair value estimate from US$14 to US$280, a very large reset in what they consider a reasonable long term outcome for the stock. This shift is being framed around improved leadership and a heavier emphasis on direct to consumer channels, while more cautious voices question how much of that story is already reflected in the higher figure. Read on to see how this evolving narrative could shape expectations and what to watch as new information...
New lymphoma results support development programmeCuris, Inc. (NASDAQ:CRIS) shares climbed 11% on Wednesday after the biotechnology company released encouraging updated clinical data for emavusertib in patients with Primary CNS Lymphoma (PCNSL) and raised enrollment expectations for its Chronic Lymphocytic Leukemia (CLL) study.
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study.
This is the newest page. Registered accounts read further back.